American Society of Hematology

banner image

Late-Breaking Abstract Submission

The deadline for late-breaking abstract submissions is October 29, 2019 at 11:59 p.m. PDT.

Learn more
banner image

61st ASH Annual Meeting & Exposition

Register now for the 2019 ASH Annual Meeting! Discounted rates available through October 31.

Learn more
banner image

2020 Highlights of ASH

Discuss the latest developments with leading hematology faculty in nine exciting locations worldwide.

Register today

Support Medical Research

Urge your members of Congress to support continued medical research funding.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 17,000 hematologists working to conquer blood diseases.

Learn more
  • The American Society of Hematology Honors Stanley L. Schrier, MD, with the 2019 Exemplary Service Award

    ASH will recognize Stanley Schrier, MD, a past ASH president and formerly Professor Emeritus of Medicine in Hematology at Stanford School of Medicine in Stanford, California, with the 2019 Exemplary Service Award for his exceptional years of service and dedication to ASH and to hematology.

  • Study finds racial disparities in treatment of multiple myeloma patients

    Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found that on average it took about three months for white patients to start novel therapy after diagnosis, while for both African Americans and Hispanics it took about five months.

  • ASH President Urges Federal Funding of Sickle Cell Data Collection Program

    Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United States Senate Committee on Appropriations to adopt the provision in the House-passed fiscal year (FY) 2020 Labor, Health and Human Services, Education, and Related Agencies appropriations bill that dedicates $2 million for a federal program to collect data on the complications, treatments, and health outcomes of people with sickle cell disease (SCD).

  • Study: Ibrutinib Linked to High Blood Pressure and Other Heart Problems

    Over half of people prescribed the targeted blood cancer-fighting drug ibrutinib developed new or worsened high blood pressure within six months of starting the medication, according to a new study published online today in Blood.

View all press releases
  • CAR T-cell Therapy: An Update on Coverage and Reimbursement

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all policy news
View all Hematologist articles